Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company HUTCHMED (China) Limited Nasdaq

Equities

HCM

US44842L1035

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 21:00:00 24/05/2024 BST 		5-day change 1st Jan Change
18.73 USD +0.05% Intraday chart for HUTCHMED (China) Limited -7.14% +3.42%
05-24 HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI
05-20 Hutchmed (China) Chairman Resigns, Successor Named MT

Business Summary

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Number of employees: 1,988

Sales per Business

HKD in Million2022Weight2023Weight Delta
Oncology/Immunology - Research and Development
43.5 %
307 9.2 % 2,853 43.5 % +829.49%
Other Ventures
36.9 %
2,056 61.6 % 2,422 36.9 % +17.81%
Oncology/Immunology - Marketed Products
19.6 %
976 29.2 % 1,285 19.6 % +31.68%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
57.9 %
3,339 100.0 % 3,796 57.9 % +13.69%
United States and Others
42.1 %
0 0.0 % 2,764 42.1 % -

Managers

Managers TitleAgeSince
Wei Guo Su CEO
 Chief Executive Officer 66 31/12/04
Chig Fung Cheng DFI
 Director of Finance/CFO 57 30/06/08
Michael Shi CTO
 Chief Tech/Sci/R&D Officer 59 31/12/21
Karen Atkin COO
 Chief Operating Officer 58 31/12/20
Edith Shih BRD
 Director/Board Member 71 31/12/99
Mark Lee IRO
 Public Communications Contact 46 -
Selina Zhang HRO
 Human Resources Officer - 28/02/22
Yiling Cui LAW
 General Counsel - -
Charles Nixon LAW
 General Counsel 54 31/12/05
May Wang PRN
 Corporate Officer/Principal 60 31/12/09

Members of the board

Members of the board TitleAgeSince
Graeme Jack BRD
 Director/Board Member 73 28/02/17
Dan Eldar CHM
 Chairman 70 31/07/16
Edith Shih BRD
 Director/Board Member 71 31/12/99
Paul Carter BRD
 Director/Board Member 63 31/01/17
Chig Fung Cheng DFI
 Director of Finance/CFO 57 30/06/08
Wei Guo Su CEO
 Chief Executive Officer 66 31/12/04
Ling Yang BRD
 Director/Board Member 44 12/07/23
Shu Kam Mok BRD
 Director/Board Member 63 31/12/16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 871,264,820 456,487,815 ( 52.39 %) 0 52.39 %

Shareholders

NameEquities%Valuation
CK HUTCHISON HOLDINGS LIMITED
38.16 %
332,478,770 38.16 % 1 286 M $
M&G Investment Management Ltd.
4.955 %
43,173,457 4.955 % 167 M $
Capital Research & Management Co. (Global Investors)
3.580 %
31,194,699 3.580 % 121 M $
Canada Pension Plan Investment Board
2.968 %
25,857,337 2.968 % 100 M $
Capital Research & Management Co. (International Investors)
1.504 %
13,102,356 1.504 % 51 M $
Bank of China Investment Management Co., Ltd.
1.066 %
9,286,500 1.066 % 36 M $
Capital International, Inc.
1.009 %
8,787,042 1.009 % 34 M $
GF Fund Management Co., Ltd.
0.9848 %
8,580,000 0.9848 % 33 M $
HuaAn Fund Management Co., Ltd.
0.7137 %
6,218,500 0.7137 % 24 M $
Penghua Fund Management Co., Ltd.
0.6877 %
5,992,000 0.6877 % 23 M $
NameEquities%Valuation
General Atlantic LLC
2.296 %
4,000,000 2.296 % 76 M $
Schroder Investment Management (Hong Kong) Ltd.
2.209 %
3,849,793 2.209 % 73 M $
Allianz Global Investors Asia Pacific Ltd.
0.8983 %
1,565,358 0.8983 % 30 M $
Bellevue Asset Management AG
0.6626 %
1,154,632 0.6626 % 22 M $
Slater Investments Ltd.
0.4616 %
804,350 0.4616 % 15 M $
Acadian Asset Management LLC
0.2794 %
486,924 0.2794 % 9 M $
AIA Investment Management Pte Ltd.
0.2153 %
375,078 0.2153 % 7 M $
Millennium Management LLC
0.2052 %
357,593 0.2052 % 7 M $
STATE STREET CORPORATION
0.1972 %
343,654 0.1972 % 7 M $
Jane Street Group LLC
0.1580 %
275,233 0.1580 % 5 M $

Company contact information

HUTCHMED (China) Ltd.

Cheung Kong Center 2 Queen's Road Central

, Hong Kong

+852 2121 8200

http://www.hutch-med.com
address HUTCHMED (China) Limited(HCM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for HUTCHMED (China) Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.773 USD
Average target price
5.651 USD
Spread / Average Target
+49.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.09% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HCM Stock
  4. HCM Stock
  5. Company HUTCHMED (China) Limited